Priority 5 from the Myeloma (Canada) PSP
| UNCERTAINTY: How can we personalize a patient's treatment based on their type of myeloma and genetic profile, and what is the impact of personalized medicine on treatment efficacy and disease outcomes? (JLA PSP Priority 5) | |
|---|---|
| Overall ranking | 5 |
| JLA question ID | 0113/5 |
| Explanatory note | Participants expressed a need to get away from the "one size fits all" approach to treatment and advocated for the use of personalized treatment which is based on their overall health status and specific type or sub-type of myeloma (e.g., IgM myeloma, kappa light chain) and customized to their unique genetic profile. |
| Evidence |
No evidence identified |
| Health Research Classification System category | Cancer and neoplasms |
| Extra information provided by this PSP | |
|---|---|
| Original uncertainty examples | The possibility to get precise target therapy ~ If it is too uncertain at this stage that is fine but wondering if different treatments per the type of myeloma have been researched. ~ Research find a way to determine which drugs would be best for me and my type of Myeloma. ~ I would like to better understand the genetic makeup of my myeloma cells to understand my prognosis and individually targeted treatment(s) ~ Is this treatment protocol for all relatively healthy patients? Is it based on any other factors? ~ My myeloma is different from someone elses. So if my MM is genetically then my treatment can be geared to me specifically. |
| Submitted by | Please see the PSP Engagement Summary on the JLA website |
| PSP information | |
|---|---|
| PSP unique ID | 0113 |
| PSP name | Myeloma (Canada) |
| Total number of uncertainties identified by this PSP. | 59 (To see a full list of all uncertainties identified, please see the detailed spreadsheet held on the JLA website) |
| Date of priority setting workshop | 28 April 2021 |